Frontier Pharma: Neurodegenerative Diseases-Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD
“Neurodegenerative Diseases Report on Global Market Status and Forecast by Players Types and Applications” newly adds in ReportsWeb.com database. This report covers leading key company profiles with information such as business overview.
(EMAILWIRE.COM, March 07, 2018 ) Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. Conditions within the therapy area are diverse, and exhibit specific pathophysiologies and etiologies, while affecting people of all ages. This report examines the entire neurodegenerative disease therapy area, with a particular focus on the three most prevalent neurodegenerative disorders: Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS). AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates.
FREE | Request Sample Copy is Available at http://www.reportsweb.com/inquiry&RW00011280189/sample
As a result there are no disease-modifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.
Scope
Unmet need is extremely high in AD and PD, with MS showing continued promise in the development of effective therapies
-What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD and MS-
-What is the current treatment algorithm-
-How effective are current therapies for these indications, and how does this impact prognosis-
The AD pipeline is large and contains a very high proportion of first-in-class product innovation.
-Which molecule types and molecular targets are most prominent across AD, PD and MS-
-What are the connections, in terms of first-in-class innovation, between AD, PD and MS-
-Which first-in-class targets are most promising-
-How does the level of first-in-class innovation change within different target classes-
-How do identified first-in-class molecular targets apply to AD, PD, MS and the wider therapeutic area-
-How does first-in-class target diversity differ by stage of development and molecular target class-
The deals landscape is active and dominated by immunomodulator products
-Which indications attract the highest deal values-
-How has deal activity fluctuated over the past decade-
-Which first-in-class pipeline products have no prior involvement in licensing or co-development deals-
Reasons to buy
-Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
-Identify leading products and key unmet needs within the market.
-Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
-Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets categorized into four major classes: protein misfolding, neuromodulators, immunomodulators and neuroprotectants. The most promising first-in-class targets are reviewed in greater detail.
-Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.
Complete Report is Available at http://www.reportsweb.com/frontier-pharma-neurodegenerative-diseases-protein-misfolding-targets-and-neuromodulators-dominate-the-first-in-class-pipeline-and-lead-the-way-as-potential-disease-modifying-therapies-in-ad-and-pd
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 7
2.1 Robust Pipeline with Attempts to Meet Unmet Needs 7
2.2 Drugs Targeting Aβ and Elements of Protein Misfolding Pathways Offer Potential New Therapies for the Treatment of AD and PD 7
2.3 Neurodegenerative Disease Pipeline Emphasizes Move Away from Conventional Areas towards Targets Related to Protein Misfolding and Neuroprotection 7
3 The Case for Innovation 9
3.1 Growing Opportunities for Biologic Products 10
3.2 Diversification of Molecular Targets 10
3.3 Innovative First-in-Class Product Development Remains Attractive 10
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 11
3.5 Sustained Innovation in Neurodegenerative Diseases 11
3.6 Publisher Report Guidance 12
4 Clinical and Commercial Landscape 13
4.1 Therapy Area Overview 13
4.1.1 Alzheimer's Disease 13
4.1.2 Parkinson's Disease 14
4.1.3 Multiple Sclerosis 14
4.2 Disease Symptoms 14
4.3 Epidemiology 15
4.3.1 Alzheimer's Disease 16
4.3.2 Parkinson's Disease 16
4.3.3 Multiple Sclerosis 16
4.4 Etiology 17
4.4.1 Alzheimer's Disease 17
4.4.2 Parkinson's Disease 18
4.4.3 Multiple Sclerosis 18
4.5 Pathophysiology 19
4.5.1 Alzheimer's Disease 19
4.5.2 Parkinson's Disease 21
4.5.3 Multiple Sclerosis 23
4.5.4 Neurodegenerative Disease Area 24
4.6 Diagnosis 25
4.6.1 Alzheimer's Disease 25
4.6.2 Parkinson's Disease 25
4.6.3 Multiple Sclerosis 26
4.7 Comorbidities and Complications 26
4.8 Prognosis 27
4.8.1 Alzheimer's Disease 27
4.8.2 Parkinson's Disease 27
4.8.3 Multiple Sclerosis 28
4.9 Treatment Options 28
4.9.1 Alzheimer's Disease 28
4.9.2 Parkinson's Disease 29
4.9.3 Multiple Sclerosis 30
4.10 Overview of Marketed Products in Neurodegeneration 31
5 Assessment of Pipeline Product Innovation 33
5.1 Overview 33
5.2 Pipeline by Stage of Development and Molecule Type 33
5.2.1 Neurodegenerative Disease Overall 33
5.2.2 Key Neurodegenerative Disease Indications 34
5.3 Pipeline by Molecular Target 36
5.3.1 Neurodegenerative Disease Overall 36
5.3.2 Key Neurodegenerative Disease Indications 39
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 40
5.5 First-in-Class Programs Targeting Novel Molecular Targets 41
6 Signaling Network and Innovation Alignment within Neurodegenerative Disease 80
6.1 Complexity of Signaling Networks in Neurodegenerative Disease 80
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 80
6.3 First-in-Class Matrix Assessment 81
7 First-in-Class Target and Pipeline Program Evaluation 86
7.1 Pipeline Programs Targeting Protein Misfolding and Aggregation 86
7.1.1 Pipeline Programs Targeting α-synuclein 86
7.1.2 Pipeline Programs Targeting Glucosylceramidase 89
7.1.3 Pipeline Programs Targeting Amyloid Precursor Protein, Amyloid Protein and Peptide, Amyloid Beta Peptide, Amyloid Beta Protein, Beta-amyloid Protein 40 and Beta-amyloid Protein 42. 91
7.2 Pipeline Programs Targeting Neuromodulators 99
7.2.1 Pipeline Programs Targeting GTP cyclohydrolase I 99
7.2.2 Pipeline Programs Targeting Acetylcholine Receptor Subunit Nicotinic Alpha-6 101
7.2.3 Pipeline Programs Targeting Metabotropic glutamate receptor 4 103
7.3 Pipeline Programs Targeting Immunomodulators 105
7.3.1 Pipeline Programs Targeting Integrin alpha m 105
7.3.2 Pipeline Programs Targeting Leukocyte immunoglobulin like receptors B1 and B2 106
7.3.3 Pipeline Program Targeting Tumor Necrosis Factor Superfamily Member 10 108
7.4 Pipeline Programs Targeting Neuroprotectants 109
7.4.1 Pipeline Programs Targeting Rho-Associated Protein Kinase 2 109
7.4.2 Pipeline Programs Targeting Angiotensin receptor type 2 111
7.5 Conclusion 112
8 Strategic Consolidations 113
8.1 Industry-Wide First-in-Class Deals 113
8.2 Licensing Deals 114
8.2.1 Deals by Region, Value and Year 114
8.2.2 Deals by Stage of Development and Value 115
8.2.3 Deals by Molecule Type, Molecular Target and Value 116
8.2.4 List of Deals with Disclosed Deal Values 117
8.3 Co-development Deals 120
8.3.1 Deals by Region, Value and Year 120
8.3.2 Deals by Stage of Development and Value 121
8.3.3 Deals by Molecule Type, Molecular Target and Value 121
8.3.4 List of Deals with Disclosed Deal Values 122
8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals 125
9 Appendix 132
9.1 References 132
9.2 Abbreviations 144
9.3 Disease List 145
9.3.1 Alzheimer's Disease 145
9.3.2 Parkinson's Disease 145
9.3.3 Multiple Sclerosis 145
9.3.4 Other 145
9.4 Top 10 First-in-Class Targets for Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis 146
9.5 Research Methodology 148
9.5.1 Data integrity 148
9.5.2 Innovative and meaningful analytical techniques and frameworks: 148
9.5.3 Evidence based analysis and insight: 148
9.6 Secondary Research 148
9.6.1 Market Analysis 148
9.6.2 Pipeline Analysis 148
9.6.3 First-in-Class Matrix Assessment 149
9.6.4 First-in-Class Target Profiles 149
9.6.5 Licensing and Co-Development Deals 149
9.7 Contact Us 149
9.8 Disclaimer 149
FREE | Request Sample Copy is Available at http://www.reportsweb.com/inquiry&RW00011280189/sample
As a result there are no disease-modifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.
Scope
Unmet need is extremely high in AD and PD, with MS showing continued promise in the development of effective therapies
-What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD and MS-
-What is the current treatment algorithm-
-How effective are current therapies for these indications, and how does this impact prognosis-
The AD pipeline is large and contains a very high proportion of first-in-class product innovation.
-Which molecule types and molecular targets are most prominent across AD, PD and MS-
-What are the connections, in terms of first-in-class innovation, between AD, PD and MS-
-Which first-in-class targets are most promising-
-How does the level of first-in-class innovation change within different target classes-
-How do identified first-in-class molecular targets apply to AD, PD, MS and the wider therapeutic area-
-How does first-in-class target diversity differ by stage of development and molecular target class-
The deals landscape is active and dominated by immunomodulator products
-Which indications attract the highest deal values-
-How has deal activity fluctuated over the past decade-
-Which first-in-class pipeline products have no prior involvement in licensing or co-development deals-
Reasons to buy
-Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
-Identify leading products and key unmet needs within the market.
-Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
-Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets categorized into four major classes: protein misfolding, neuromodulators, immunomodulators and neuroprotectants. The most promising first-in-class targets are reviewed in greater detail.
-Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.
Complete Report is Available at http://www.reportsweb.com/frontier-pharma-neurodegenerative-diseases-protein-misfolding-targets-and-neuromodulators-dominate-the-first-in-class-pipeline-and-lead-the-way-as-potential-disease-modifying-therapies-in-ad-and-pd
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 7
2.1 Robust Pipeline with Attempts to Meet Unmet Needs 7
2.2 Drugs Targeting Aβ and Elements of Protein Misfolding Pathways Offer Potential New Therapies for the Treatment of AD and PD 7
2.3 Neurodegenerative Disease Pipeline Emphasizes Move Away from Conventional Areas towards Targets Related to Protein Misfolding and Neuroprotection 7
3 The Case for Innovation 9
3.1 Growing Opportunities for Biologic Products 10
3.2 Diversification of Molecular Targets 10
3.3 Innovative First-in-Class Product Development Remains Attractive 10
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 11
3.5 Sustained Innovation in Neurodegenerative Diseases 11
3.6 Publisher Report Guidance 12
4 Clinical and Commercial Landscape 13
4.1 Therapy Area Overview 13
4.1.1 Alzheimer's Disease 13
4.1.2 Parkinson's Disease 14
4.1.3 Multiple Sclerosis 14
4.2 Disease Symptoms 14
4.3 Epidemiology 15
4.3.1 Alzheimer's Disease 16
4.3.2 Parkinson's Disease 16
4.3.3 Multiple Sclerosis 16
4.4 Etiology 17
4.4.1 Alzheimer's Disease 17
4.4.2 Parkinson's Disease 18
4.4.3 Multiple Sclerosis 18
4.5 Pathophysiology 19
4.5.1 Alzheimer's Disease 19
4.5.2 Parkinson's Disease 21
4.5.3 Multiple Sclerosis 23
4.5.4 Neurodegenerative Disease Area 24
4.6 Diagnosis 25
4.6.1 Alzheimer's Disease 25
4.6.2 Parkinson's Disease 25
4.6.3 Multiple Sclerosis 26
4.7 Comorbidities and Complications 26
4.8 Prognosis 27
4.8.1 Alzheimer's Disease 27
4.8.2 Parkinson's Disease 27
4.8.3 Multiple Sclerosis 28
4.9 Treatment Options 28
4.9.1 Alzheimer's Disease 28
4.9.2 Parkinson's Disease 29
4.9.3 Multiple Sclerosis 30
4.10 Overview of Marketed Products in Neurodegeneration 31
5 Assessment of Pipeline Product Innovation 33
5.1 Overview 33
5.2 Pipeline by Stage of Development and Molecule Type 33
5.2.1 Neurodegenerative Disease Overall 33
5.2.2 Key Neurodegenerative Disease Indications 34
5.3 Pipeline by Molecular Target 36
5.3.1 Neurodegenerative Disease Overall 36
5.3.2 Key Neurodegenerative Disease Indications 39
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 40
5.5 First-in-Class Programs Targeting Novel Molecular Targets 41
6 Signaling Network and Innovation Alignment within Neurodegenerative Disease 80
6.1 Complexity of Signaling Networks in Neurodegenerative Disease 80
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 80
6.3 First-in-Class Matrix Assessment 81
7 First-in-Class Target and Pipeline Program Evaluation 86
7.1 Pipeline Programs Targeting Protein Misfolding and Aggregation 86
7.1.1 Pipeline Programs Targeting α-synuclein 86
7.1.2 Pipeline Programs Targeting Glucosylceramidase 89
7.1.3 Pipeline Programs Targeting Amyloid Precursor Protein, Amyloid Protein and Peptide, Amyloid Beta Peptide, Amyloid Beta Protein, Beta-amyloid Protein 40 and Beta-amyloid Protein 42. 91
7.2 Pipeline Programs Targeting Neuromodulators 99
7.2.1 Pipeline Programs Targeting GTP cyclohydrolase I 99
7.2.2 Pipeline Programs Targeting Acetylcholine Receptor Subunit Nicotinic Alpha-6 101
7.2.3 Pipeline Programs Targeting Metabotropic glutamate receptor 4 103
7.3 Pipeline Programs Targeting Immunomodulators 105
7.3.1 Pipeline Programs Targeting Integrin alpha m 105
7.3.2 Pipeline Programs Targeting Leukocyte immunoglobulin like receptors B1 and B2 106
7.3.3 Pipeline Program Targeting Tumor Necrosis Factor Superfamily Member 10 108
7.4 Pipeline Programs Targeting Neuroprotectants 109
7.4.1 Pipeline Programs Targeting Rho-Associated Protein Kinase 2 109
7.4.2 Pipeline Programs Targeting Angiotensin receptor type 2 111
7.5 Conclusion 112
8 Strategic Consolidations 113
8.1 Industry-Wide First-in-Class Deals 113
8.2 Licensing Deals 114
8.2.1 Deals by Region, Value and Year 114
8.2.2 Deals by Stage of Development and Value 115
8.2.3 Deals by Molecule Type, Molecular Target and Value 116
8.2.4 List of Deals with Disclosed Deal Values 117
8.3 Co-development Deals 120
8.3.1 Deals by Region, Value and Year 120
8.3.2 Deals by Stage of Development and Value 121
8.3.3 Deals by Molecule Type, Molecular Target and Value 121
8.3.4 List of Deals with Disclosed Deal Values 122
8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals 125
9 Appendix 132
9.1 References 132
9.2 Abbreviations 144
9.3 Disease List 145
9.3.1 Alzheimer's Disease 145
9.3.2 Parkinson's Disease 145
9.3.3 Multiple Sclerosis 145
9.3.4 Other 145
9.4 Top 10 First-in-Class Targets for Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis 146
9.5 Research Methodology 148
9.5.1 Data integrity 148
9.5.2 Innovative and meaningful analytical techniques and frameworks: 148
9.5.3 Evidence based analysis and insight: 148
9.6 Secondary Research 148
9.6.1 Market Analysis 148
9.6.2 Pipeline Analysis 148
9.6.3 First-in-Class Matrix Assessment 149
9.6.4 First-in-Class Target Profiles 149
9.6.5 Licensing and Co-Development Deals 149
9.7 Contact Us 149
9.8 Disclaimer 149
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results